KATHLEEN P. BLOCH APPOINTED AS CHIEF FINANCIAL OFFICER OF CYTOSORBENTS MONMOUTH JUNCTION, NEW JERSEY (

KATHLEEN P. BLOCH APPOINTED AS CHIEF

FINANCIAL OFFICER OF CYTOSORBENTS

MONMOUTH JUNCTION, NEW JERSEY (May

13, 2013) - CytoSorbents Corporation (OTCBB: CTSO), a critical care focused therapeutic device company using blood purification

to treat life-threatening illnesses, today announced the appointment of Kathleen P. Bloch, MBA, CPA, as its Chief Financial Officer,

effective May 29, 2013.

Ms. Bloch has more than 20 years

of executive financial experience in both public and private companies. Most recently, she was Chief Financial Officer of Laureate

Biopharmaceutical Services, Inc., a leader in biopharmaceutical contract development and manufacturing. Previously, Ms.

Bloch was Chief Operating Officer and CFO of PC Group, Inc., a $70 million in revenue, NASDAQ-listed, publicly traded company with

a diverse group of holdings, including several medical device subsidiaries. Prior to that, Ms. Bloch was CFO of Silver Line Building

Products Corporation for seven years, helping it grow from $100 million in sales, into the world's largest manufacturer of

vinyl windows with more than $750 million in revenue, employing over 7,000 people nationwide in 35 states with nine manufacturing

facilities. In 2006, she oversaw the acquisition of Silver Line by Andersen Corporation, a leading international manufacturer of

windows. Previously, Ms. Bloch was CFO of ERD Waste Corporation, a NASDAQ-listed, publicly-traded environmental services provider,

operating in 16 states with more than $60 million in sales. She began her career at Peat Marwick International, which became KPMG

LLP, one of the big four accounting firms. Ms. Bloch holds a Master of Business Administration degree and a Bachelor of Science

Accounting degree from LaSalle University, and is a Certified Public Accountant.

Ms. Bloch commented, "I am delighted

to be joining CytoSorbents at this critical juncture as it accelerates commercialization of CytoSorb . I will add my financial

leadership and management expertise as part of this excellent team and begin to contribute to the international growth initiatives

that are underway, help drive a rapid growth strategy, and create significant shareholder value."

"Kathy has a proven track record of driving growth at

successful companies," stated Al Kraus, CytoSorbents' Chairman of the Board. "In addition, she now rounds out

our already strong expanded management team, bringing valuable experience in corporate finance, operations, governance, and compliance

to the Company. She will undoubtedly make some outstanding contributions to the Company, and we are pleased to have her on board."

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, remarked,

"We are very excited to welcome Kathy as CFO. Throughout her career, she has impressively managed and helped finance a variety

of rapid growth companies, some extremely complex, and has developed an outstanding background in manufacturing. This is an excellent

match for our current and future needs. In addition, her personality, energy and enthusiasm, coupled with her extensive experience,

business acumen and skills, is an excellent fit for our management team, and will contribute to the success of our long-term strategic

Dr. Chan added, "The Company and the Board of Directors

also extends its sincere appreciation to Mr. Ronald Berger for his excellent performance and dedication as Interim CFO for the

past several months."

About CytoSorbents Corporation

CytoSorbents Corporation is a critical

care focused therapeutic device company using blood purification to control a poorly-regulated immune system and fight multi-organ

failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that

can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. CytoSorb , the Company's

flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce

the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses

such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high,

yet no effective treatments exist. Additional information is available for download on the Company's website: http://www.cytosorbents.com

Forward-Looking Statements

release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private

Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and

are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These

statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes

in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ

materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed

with the SEC on April 3, 2013, which is available at http://www.sec.gov.

CytoSorbents Corporation

Chief Executive Officer

(732) 329-8885 ext. *823

Alliance Advisors, LLC